# Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT

Study · id `cardio:ct-nct07168278` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07168278](<https://clinicaltrials.gov/study/NCT07168278>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07168278

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 794 participants.

## Technical summary

Registry record NCT07168278. Randomized; single masking; primary purpose treatment. Start 2025-11-01 (anticipated); primary completion 2028-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 794 participants (planned count; ClinicalTrials.gov record NCT07168278, source copy `cardio:ctgov-nct07168278-2025-09-11`, retrieved 2026-10-26)
- Planned start: 2025-11-01 (anticipated) (ClinicalTrials.gov record NCT07168278, source copy `cardio:ctgov-nct07168278-2025-09-11`, retrieved 2026-10-26)
- Primary completion: 2028-03-01 (anticipated) (ClinicalTrials.gov record NCT07168278, source copy `cardio:ctgov-nct07168278-2025-09-11`, retrieved 2026-10-26)
- Completion: 2028-05-31 (anticipated) (ClinicalTrials.gov record NCT07168278, source copy `cardio:ctgov-nct07168278-2025-09-11`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07168278, source copy `cardio:ctgov-nct07168278-2025-09-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07168278-2025-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT
- Acronym: TNK LATE
- Condition: Acute Ischemic Stroke
- Condition: Large Vessel Occlusion
- Condition: Tenecteplase
- Condition: Thrombolysis
- Intervention (Drug): TNK
- Intervention (Drug): Standard medical treatment
- Lead sponsor: The First Affiliated Hospital of University of Science and Technology of China
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital of University of Science and Technology of China (`cardio:org-the-first-affiliated-hospital-of-university-of-science-and-03d159`)

## Provenance

Content hash: b0dff4de57d9d8ac83692a7705383cbd0bf00130f8b852ac0ef2121504609509
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
